Teva Releases Q1 2025 Aide Memoire
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) has announced the release of its Q1 2025 Aide Memoire, now available on the company's investor relations webpage. The document is designed to assist in financial modeling of quarterly results, incorporating previous performance data, management commentary on business outlook, and select third-party source information.
The company has indicated its intention to provide this information regularly towards the end of each quarter going forward.
Teva Pharmaceutical Industries (NYSE e TASE: TEVA) ha annunciato il rilascio del suo Aide Memoire per il primo trimestre del 2025, ora disponibile sulla pagina web delle relazioni con gli investitori dell'azienda. Il documento è progettato per assistere nella modellazione finanziaria dei risultati trimestrali, incorporando dati di performance precedenti, commenti della direzione sulle prospettive aziendali e informazioni selezionate da fonti esterne.
L'azienda ha indicato la sua intenzione di fornire queste informazioni regolarmente verso la fine di ogni trimestre in futuro.
Teva Pharmaceutical Industries (NYSE y TASE: TEVA) ha anunciado la publicación de su Aide Memoire del primer trimestre de 2025, ahora disponible en la página web de relaciones con inversores de la compañía. El documento está diseñado para ayudar en la modelización financiera de los resultados trimestrales, incorporando datos de rendimiento anteriores, comentarios de la dirección sobre las perspectivas del negocio y selecta información de fuentes externas.
La empresa ha indicado su intención de proporcionar esta información de manera regular al final de cada trimestre en adelante.
테바 제약 산업 (NYSE 및 TASE: TEVA)는 2025년 1분기 Aide Memoire의 출시를 발표했으며, 현재 회사의 투자자 관계 웹페이지에서 확인할 수 있습니다. 이 문서는 분기별 실적의 재무 모델링을 지원하기 위해 설계되었으며, 이전 성과 데이터, 경영진의 비즈니스 전망에 대한 논평 및 선택된 제3자 정보가 포함되어 있습니다.
회사는 앞으로 매 분기 말에 이러한 정보를 정기적으로 제공할 의향이 있음을 밝혔습니다.
Teva Pharmaceutical Industries (NYSE et TASE : TEVA) a annoncé la publication de son Aide Memoire pour le premier trimestre 2025, maintenant disponible sur la page web des relations avec les investisseurs de l'entreprise. Ce document est conçu pour aider à la modélisation financière des résultats trimestriels, en intégrant des données de performance antérieures, des commentaires de la direction sur les perspectives commerciales et des informations sélectionnées provenant de sources tierces.
L'entreprise a indiqué son intention de fournir ces informations régulièrement à la fin de chaque trimestre à l'avenir.
Teva Pharmaceutical Industries (NYSE und TASE: TEVA) hat die Veröffentlichung seines Aide Memoire für das erste Quartal 2025 angekündigt, das jetzt auf der Investor-Relations-Webseite des Unternehmens verfügbar ist. Das Dokument ist darauf ausgelegt, bei der finanziellen Modellierung der Quartalsergebnisse zu unterstützen, indem es frühere Leistungsdaten, Kommentare des Managements zur Geschäftsaussicht und ausgewählte Informationen von Drittanbietern einbezieht.
Das Unternehmen hat seine Absicht bekundet, diese Informationen künftig regelmäßig zum Ende jedes Quartals bereitzustellen.
- None.
- None.
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the “Investors” page on its website.
Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independent sources. Going forward, it is Teva’s intention to provide this information towards the end of each quarter.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients’ needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Risk Factors” and " Forward-looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquires
TevaIR@Tevapharm.com
FAQ
What is the purpose of TEVA's Q1 2025 Aide Memoire?
Where can investors access TEVA's Q1 2025 Aide Memoire?
How frequently will TEVA release the Aide Memoire documents?
What information does TEVA's Q1 2025 Aide Memoire contain?
